Trajectory of Frailty and Cognitive Dysfunction in Older Adults

March 5, 2024 updated by: Zheng Li

Study of the Joint Trajectory of Frailty and Cognitive Dysfunction Among Community-dwelling Older Adults

To explore the heterogeneity of the development trend of frailty and cognitive function of older adults.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

According to the inclusion and exclusion criteria, the older adults will be selected from community health service centers in four districts of Beijing. Frailty and cognitive function of the older adults will be assessed for a 24-month longitudinal multi-time (baseline, 6, 12 and 24 months). The heterogeneity of the development trend of frailty and cognitive function will be explored, and the subgroups of joint development trajectory of frailty and cognitive impairment will be classified, so as to identify high-risk populations that need to be managed.

Study Type

Observational

Enrollment (Estimated)

934

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Older adults without clear diagnosis of any type of dementia, neurological diseases, and mental disorders that affecting cognitive function.

Description

Inclusion Criteria:

  • Age ≥60 years.
  • Older adults with clear consciousness, ability of simple written and verbal communication.
  • They volunteered to participate in this study, and signed an informed consent.

Exclusion Criteria:

  • A clear diagnosis of any type of dementia.
  • There are neurological diseases that clearly lead to cognitive dysfunction, such as severe cerebrovascular disease, brain trauma, intracranial tumors, etc.
  • They have been clearly diagnosed with mental disorders affecting cognitive function, including schizophrenia, depression, bipolar disorder, etc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Older adults
Older adults without clear diagnosis of any type of dementia, neurological diseases, and mental disorders that affecting cognitive function.
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frailty
Time Frame: Baseline, 6 month, 12 month, and 24 month
Frailty was evaluated by the Fried phenotype model, which was proposed and validated by Fried and colleagues, and is the most widely adopted model, generally regarded as the standard model for physical frailty. In Fried's model, the frailty phenotype is based on the following five components: slowness (gait speed), weakness (hand grip), weight loss, exhaustion, and low physical activity.
Baseline, 6 month, 12 month, and 24 month
Cognitive function
Time Frame: Baseline, 6 month, 12 month, and 24 month

The method to assess objective cognitive function is Montreal Cognitive Assessment-Beijing version for Chinese, which is a classical tool to screen for MCI, including 7 cognitive domains (visuospatial and executive function, naming, attention, language, abstraction, delayed recall, and orientation). The total score of the scale is 30, with higher scores indicating better cognitive function. The Mini-Mental State Examination (MMSE) which included 30 questions to measure the cognitive status will be also performed to assess objective cognitive function.

In addition, We use the 9-items subjective cognitive decline questionnaire (SCD-Q9) to measure the symptoms of subjective cognition. The SCD-Q9 is a simple and quick screening scale to identify those who suffer from MCI from general populations. SCD-Q9 lists the 9 core items of SCD symptoms and contains 2 dimensions and 9 items.

Baseline, 6 month, 12 month, and 24 month

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Activities of daily life (ADLs)
Time Frame: Baseline, 6 month, 12 month, and 24 month
The Chinese version of the ADLs scale revised by Zhang will be utilized to identify the ability to perform the activities. A summary score for each item ranges from 1 (require no help) to 4 (unable to do it at all) points. The first eight items measure Basic Activities of Daily Living (BADLs), with a total score of 8~32. The last 12 items are about Instrumental Activities of Daily Living (IADLs), with a total score of 12~48. The lower the score, the lower the degree of dependence on daily life.
Baseline, 6 month, 12 month, and 24 month
Anxiety
Time Frame: Baseline, 6 month, 12 month, and 24 month
General anxiety disorder-7 (GAD-7) will be utilized, which is a seven-question screening tool that identifies whether a complete assessment for anxiety is indicated. Scoring Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
Baseline, 6 month, 12 month, and 24 month
Apathy
Time Frame: Baseline, 6 month, 12 month, and 24 month
The apathy subscale (GDS-3A) of the GDS-15 consists of the following three items (score range 0-3 points) will be utilized: (i) Have you dropped many of your activities and interests?; (ii) Do you prefer to stay at home, rather than going out and doing new things?; and (iii) Do you feel full of energy?.
Baseline, 6 month, 12 month, and 24 month
Perceived social support
Time Frame: Baseline, 6 month, 12 month, and 24 month
The perceived social support scale (PSSS) consists of 12 items, which are divided into three dimensions: family support, friends support and other support. The scale was developed by Zimet et al. and has a favourable internal consistency (Cronbach's α = 0.85-0.91). Each item is scored from 1 (strongly disagree) to 7 (strongly agree), and the total score ranges from 7 to 84. The higher the score is, the higher the level of social support the individual feels.
Baseline, 6 month, 12 month, and 24 month
Social network
Time Frame: Baseline, 6 month, 12 month, and 24 month
Lubben Social Network Scale (LSNS-6) includes a set of three items on family and a comparable set of three items on friends, asking about frequency of contact and emotional closeness. More specifically, the items address the number of network members whom the respondent (a) sees or hears from at least once a month, (b) feels at ease talking about private matters, and (c) feels close enough to call for help. The respondent answered each question by selecting a value on a 6-point scale (ranging from 0 = none to 5 = nine or more). Each family/friend subscale could range from 0 to 15, and the total score from 0 to 30. Higher scores indicate stronger ties with family or friends.
Baseline, 6 month, 12 month, and 24 month
Health status and life style
Time Frame: Baseline, 6 month, 12 month, and 24 month
Data on health status (disease, hearing) and lifestyle (diet, sleep, exercise) of the elderly were obtained through self-made questionnaires.
Baseline, 6 month, 12 month, and 24 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Zheng Li, Chinese Academy of Medical Sciences & Peking Union Medical College

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 15, 2024

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

February 18, 2024

First Submitted That Met QC Criteria

February 18, 2024

First Posted (Actual)

February 23, 2024

Study Record Updates

Last Update Posted (Actual)

March 7, 2024

Last Update Submitted That Met QC Criteria

March 5, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Dysfunction

Clinical Trials on No intervention

3
Subscribe